Cargando…
An open-label, sequential, dose-finding study of peginesatide for the maintenance treatment of anemia in chronic hemodialysis patients
BACKGROUND: Peginesatide is a peptide-based erythropoiesis-stimulating agent that was designed and engineered to stimulate specifically the erythropoietin receptor dimer that governs erythropoiesis. The primary objective of this phase 2 dose-finding study was to determine the once-monthly peginesati...
Autores principales: | Besarab, Anatole, Zeig, Steven N, Martin, Edouard R, Pergola, Pablo E, Whittier, Frederick C, Zabaneh, Raja I, Schiller, Brigitte, Mayo, Martha, Francisco, Carol A, Polu, Krishna R, Duliege, Anne-Marie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3511162/ https://www.ncbi.nlm.nih.gov/pubmed/22935486 http://dx.doi.org/10.1186/1471-2369-13-95 |
Ejemplares similares
-
Profile of peginesatide and its potential for the treatment of anemia in adults with chronic kidney disease who are on dialysis
por: Mikhail, Ashraf
Publicado: (2012) -
Managing dialysis patients who develop anemia caused by chronic kidney disease: focus on peginesatide
por: Valliant, Amanda, et al.
Publicado: (2013) -
Lessons learned from peginesatide in the treatment of anemia associated with chronic
kidney disease in patients on dialysis
por: Kaushik, Tarun, et al.
Publicado: (2013) -
Effects of Peginesatide Injection on QTc Interval in Healthy Adults
por: Czerniak, Richard, et al.
Publicado: (2014) -
Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients
por: Besarab, Anatole, et al.
Publicado: (2015)